

Rhythm Establishes UK subsidiary for Market Entry

Highlights

- ✓ **100% fully owned subsidiary, Rhythm Biosciences UK Limited established; and**
- ✓ **Over 61% of Colorectal Cancer cases each year in the UK fall outside the eligible screening population (60-74 years).**

Transformative cancer diagnostics technology company, Rhythm Biosciences Ltd (**ASX: RHY**) (**Rhythm** or the **Company**) is pleased to confirm it has further progressed its market entry strategy for ColoSTAT® in the United Kingdom (UK) with the establishment of a 100% fully owned UK Subsidiary, with Otto Buttula and Paul Smith as directors of the Company.

Rhythm Biosciences UK Limited, was established in June 2023 to assist in the importation and distribution channels of ColoSTAT® into the UK and other parts of Europe.

Having a local presence in the UK will provide the parent company the opportunity to engage directly with local customers and direct involvement with the supply chain requirements of ColoSTAT®.

Colorectal Cancer in the UK

The UK (England, Scotland, Wales, and Northern Ireland) has a population of approximately 10.7 million people in the current addressable Colorectal Cancer (CRC) screening market aged from 60 to 74. The UK utilises the Faecal Immunochemical Test (FIT) as a screening methodology with an approximate participation rate of 67%.¹

Bowel Cancer Statistics (UK)	England	Scotland	Wales	Northern Ireland	TOTAL UK
Population (million)	56.00	5.50	3.10	1.90	67.00
Eligible Screening Population (million) (60-74 years)	8.85	0.96	0.56	0.29	10.66
% Screened of eligible population	69.20%	60.00%	52.18%	60.00%	67.23%
Population screened (million)	6.12	0.57	0.29	0.17	7.16
Unscreened Eligible Population (million)	2.73	0.38	0.27	0.12	3.49
CRC Cases	35,496	3,884	2,325	1,181	42,886
CRC Incidence (60-74 years)	13,640	1,525	983	473	16,621
CRC Incidence outside Screening population	21,856	2,359	1,342	708	26,264
CRC Incidence outside Screening population	61.6%	60.7%	57.7%	59.9%	61.2%

Rhythm Biosciences Ltd
 ACN 619 459 335
 ASX: RHY

www.rhythmbio.com

Australian Registered Address

Bio21 Molecular Science & Biotechnology Institute
 30 Flemington Road
 Parkville VIC 3010 Australia

T +61 3 8256 2880
 E info@rhythmbio.com

Directors

Otto Buttula
 Trevor Lockett
 Rachel David
 Louis Panaccio
 Sue MacLeman

Executive Chairman
 Executive Director
 Non-Executive Director
 Non-Executive Director
 Non-Executive Director

Despite the favourable screening participation rate in the eligible patient population (60–74 years), over 61% of those diagnosed with CRC fall outside the screening population. The CRC statistics vary between the four UK countries (see table), however the common feature is that most CRC cases are among the unscreened population.²

Chief Financial Officer of Rhythm, Mr Paul Smith, commented: *“This is an important step in our launch strategy for ColoSTAT® in the UK and Europe. Our established subsidiary will provide Rhythm with a critical regional base from which to deliver our simple blood test for CRC to the UK and wider European markets.”*

- ENDS -

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investor@rhythmbio.com or on +61 3 8256 2880:

Mr Otto Buttula Executive Chairman	Ms Elena Deak Chief Commercial Officer	Mr Paul Smith CFO & Company Secretary
--	--	---

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and Twitter.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience’s simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT® Test-Kit is based on research from Australia’s CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

1 <https://www.cancerresearchuk.org>

2 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894790/>